loader
Please Wait
Applying Filters...

Evonik Evonik

X

Technical details about Selamectin, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
1. Also known as: Revolution, 220119-17-5, Uk-124,114, 165108-07-6, Uk-124114, A2669owx9n
Molecular Formula
C43H63NO11
Molecular Weight
770.0  g/mol
InChI Key
AFJYYKSVHJGXSN-XHKIUTQPSA-N
FDA UNII
A2669OWX9N

Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats. It also removes 2 types of lungworm in cats and one type of lungworm in dogs. It is distributed by Zoetis, a former Pfizer subsidiary. It is structurally related to ivermectin and milbemycin. Selamectin is not approved for human use.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1R,4S,5'S,6R,6'S,8R,10E,12S,13S,14E,16E,20R,21Z,24S)-6'-cyclohexyl-24-hydroxy-21-hydroxyimino-12-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
2.1.2 InChI
InChI=1S/C43H63NO11/c1-24-11-10-14-30-23-50-40-36(44-48)27(4)19-33(43(30,40)47)41(46)52-32-20-31(16-15-25(2)38(24)53-35-21-34(49-6)37(45)28(5)51-35)54-42(22-32)18-17-26(3)39(55-42)29-12-8-7-9-13-29/h10-11,14-15,19,24,26,28-29,31-35,37-40,45,47-48H,7-9,12-13,16-18,20-23H2,1-6H3/b11-10+,25-15+,30-14+,44-36-/t24-,26-,28-,31+,32-,33-,34-,35-,37-,38-,39-,40+,42+,43+/m0/s1
2.1.3 InChI Key
AFJYYKSVHJGXSN-XHKIUTQPSA-N
2.1.4 Canonical SMILES
CC1CCC2(CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5=NO)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)O)OC)C)OC1C7CCCCC7
2.1.5 Isomeric SMILES
C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]\5[C@@]4([C@@H](C=C(/C5=N/O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)\C)O[C@@H]1C7CCCCC7
2.2 Other Identifiers
2.2.1 UNII
A2669OWX9N
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 Monosaccharide

2.3.2 Depositor-Supplied Synonyms

1. Revolution

2. 220119-17-5

3. Uk-124,114

4. 165108-07-6

5. Uk-124114

6. A2669owx9n

7. Unii-a2669owx9n

8. Stronghold

9. (1r,4s,5's,6r,6's,8r,10e,12s,13s,14e,16e,20r,21z,24s)-6'-cyclohexyl-24-hydroxy-21-hydroxyimino-12-[(2r,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one

10. Ncgc00095066-01

11. 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 Monosaccharide

12. Revolution (antibiotic)

13. Selamectin [mi]

14. Selamectin [inn]

15. Selamectin (usan/inn)

16. Selamectin [usan]

17. Selamectin [mart.]

18. Dsstox_cid_25903

19. Dsstox_rid_81215

20. Selamectin [usp-rs]

21. Dsstox_gsid_45903

22. Schembl120105

23. Selamectin [usan:inn:ban]

24. Selamectin [green Book]

25. Chembl1908325

26. Dtxsid6045903

27. Chebi:177562

28. Selamectin [usp Monograph]

29. Ex-a3581

30. Tox21_111408

31. Mfcd31621085

32. Zinc85537134

33. Stronghold Component Selamectin

34. Akos026749796

35. Cs-7778

36. Db11459

37. Nsc 758615

38. Selamectin [ema Epar Veterinary]

39. Selamectin Component Of Stronghold

40. (2ae,4e,5's,6s,6's,7s,8e,11r,13r,15s,17ar,20ar,20bs)-6'-cyclohexyl-7-((2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)oxy)-3',4',5',6,6',7,10,11,14,15,20a,20b-dodecahydro-20b-hydroxy-5',6,8,19-tetramethylspiro(11,15-methano-2h,13h,17h-furo(4,3,2-pq)(2,6)benzodioxacyclooctadecin-13,2'-(2h)pyran)-17,20(17ah)-dione 20-oxime

41. 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin A1a

42. Avermectin A1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-.alpha.-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-

43. Selamectin 100 Microg/ml In Acetonitrile

44. Stronghold Plus Component Selamectin

45. Hy-107212

46. Uk 124114

47. Cas-165108-07-6

48. Selamectin Component Of Stronghold Plus

49. D05813

50. J-014423

51. Avermectin A1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-.alpha.-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5(hydroxyimino)-, (5z)-

52. Avermectin A1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-, (5z)-

2.4 Create Date
2006-10-24
3 Chemical and Physical Properties
Molecular Weight 770.0 g/mol
Molecular Formula C43H63NO11
XLogP35.4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count12
Rotatable Bond Count4
Exact Mass769.44011183 g/mol
Monoisotopic Mass769.44011183 g/mol
Topological Polar Surface Area155 Ų
Heavy Atom Count55
Formal Charge0
Complexity1550
Isotope Atom Count0
Defined Atom Stereocenter Count14
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count4
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

- Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven week of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in area to which the animal has access.

- Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration. The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.

- Treatment of ear mites (Otodectes cynotis).

Cats:

- Treatment of biting lice infestations (Felicola subrostratus)

- Treatment of adult roundworms (Toxocara cati)

- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).

Dogs:

- Treatment of biting lice infestations (Trichodectes canis)

- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)

- Treatment of adult intestinal roundworms (Toxocara canis).


* Cats and dogs: :

* Treatment and prevention of flea infestations: caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.

* Prevention of heartworm disease: caused by Dirofilaria immitis with monthly administration.

The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.

* Treatment of ear mites: (Otodectes cynotis).

* Cats: :

- Treatment of biting lice infestations (Felicola subrostratus)

- Treatment of adult roundworms (Toxocara cati)

- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme)

- Treatment of biting lice infestations (Trichodectes canis)

- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)


* Cats and dogs: :

-

* Treatment and prevention of flea infestations: caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.

-

* Prevention of heartworm disease: caused by Dirofilaria immitis with monthly administration. Stronghold may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with Stronghold. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when Stronghold has been administered monthly. This product is not effective against adult D. immitis.

-

* Treatment of ear mites: (Otodectes cynotis).

*:

* Cats: :

- Treatment of biting lice infestations (Felicola subrostratus

- Treatment of adult roundworms (Toxocaracati)

- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).

*:

* Dogs: :

- Treatment of biting lice infestations (Trichodectes canis)

- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)

- Treatment of adult intestinal roundworms (Toxocara canis).


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antiparasitic Agents

Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)


5.2 ATC Code

QP54AA05


QP54AA05


QP54AA05


Post Enquiry
POST ENQUIRY